Takeda Pharmaceutical Shares Outstanding 2007-2019 | TAK

Takeda Pharmaceutical shares outstanding history from 2007 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Takeda Pharmaceutical shares outstanding for the quarter ending December 31, 2019 were 3.115B, a 99.2% increase year-over-year.
  • Takeda Pharmaceutical 2019 shares outstanding were 1.934B, a 22.9% increase from 2018.
  • Takeda Pharmaceutical 2018 shares outstanding were 1.573B, a 0.1% increase from 2017.
  • Takeda Pharmaceutical 2017 shares outstanding were 1.572B, a 0.29% decline from 2016.
Takeda Pharmaceutical Annual Shares Outstanding
(Millions of Shares)
2019 1,934
2018 1,573
2017 1,572
2016 1,576
2015 1,573
2014 1,581
2013 1,579
2012 1,579
2011 1,579
2010 1,579
2009 1,617
2008 1,697
2007 1,740
2006 1,772
Takeda Pharmaceutical Quarterly Shares Outstanding
(Millions of Shares)
Q3 2019 3,115
Q2 2019 3,124
Q1 2019 3,111
Q3 2018 1,573
Q1 2018 1,564
Q1 2017 1,560
Q1 2016 1,564
Q1 2015 1,570
Q4 2015 1,574
Q3 2014 1,578
Q2 2014 1,572
Q1 2014 1,575
Q4 2014 1,578
Q3 2013 1,581
Q2 2013 1,578
Q1 2013 1,581
Q4 2013 1,580
Q3 2012 1,579
Q2 2012 1,579
Q1 2012 1,579
Q4 2012 1,579
Q3 2011 1,578
Q2 2011 1,582
Q4 2011 1,579
Q4 2010 1,579
Q2 2009 6
Q4 2009 1,588
Q4 2008 1,940
Q4 2007 1,716
Q4 2006 1,790
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $54.955B $18.875B
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $63.617B 36.80
Astellas Pharma (ALPMY) Japan $29.466B 14.72
Eisai (ESALY) Japan $21.073B 40.62
UCB SA (UCBJF) Belgium $18.905B 0.00
Grifols, S.A (GRFS) Spain $16.144B 21.15
Merck (MKGAF) Germany $15.852B 21.63
Ono Pharmaceutical (OPHLF) Japan $11.311B 24.18
Neurocrine Biosciences (NBIX) United States $8.486B 235.77
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.449B 0.00
Catalent (CTLT) United States $7.680B 31.60
Ionis Pharmaceuticals (IONS) United States $7.496B 22.49
Jazz Pharmaceuticals (JAZZ) Ireland $6.349B 7.74
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.877B 0.00
Orion OYJ (ORINY) Finland $5.871B 30.12
IPSEN SA ADR (IPSEY) France $5.641B 0.00
STADA ARZNEIMI (STDAF) Germany $5.543B 0.00
Hypermarcas (HYPMY) Brazil $4.584B 13.94
United Therapeutics (UTHR) United States $4.423B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $3.660B 67.93
Evotec AG (EVTCY) Germany $3.643B 58.78
Nektar Therapeutics (NKTR) United States $3.612B 0.00
FibroGen (FGEN) United States $3.539B 104.00
PTC Therapeutics (PTCT) United States $3.300B 0.00
Sage Therapeutics (SAGE) United States $2.695B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.675B 10.82
ChemoCentryx (CCXI) United States $2.565B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.955B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.883B 22.89
Xencor (XNCR) United States $1.833B 74.86
Pacira Pharmaceuticals (PCRX) United States $1.800B 49.22
Heron Therapeutics (HRTX) United States $1.615B 0.00
Corcept Therapeutics (CORT) United States $1.529B 17.10
Tilray (TLRY) Canada $1.461B 0.00
Esperion Therapeutics (ESPR) United States $1.429B 0.00
USANA Health Sciences (USNA) United States $1.402B 14.72
CLINIGEN GP (CLIGF) United Kingdom $1.392B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.358B 0.00
Endo (ENDP) Ireland $1.277B 2.36
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.134B 15.79
Zogenix (ZGNX) United States $1.048B 0.00
Karyopharm Therapeutics (KPTI) United States $1.008B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.993B 30.75
Akebia Therapeutics (AKBA) United States $0.987B 0.00
Radius Health (RDUS) United States $0.911B 0.00
Portola Pharmaceuticals (PTLA) United States $0.791B 0.00
Aerie Pharmaceuticals (AERI) United States $0.790B 0.00
Collegium Pharmaceutical (COLL) United States $0.727B 0.00
ImmunoGen (IMGN) United States $0.657B 0.00
Flexion Therapeutics (FLXN) United States $0.592B 0.00
Molecular Templates (MTEM) United States $0.579B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.511B 0.00
TherapeuticsMD (TXMD) United States $0.451B 0.00
Ardelyx (ARDX) United States $0.440B 0.00
Translate Bio (TBIO) United States $0.435B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.431B 52.25
BioSpecifics Technologies Corp (BSTC) United States $0.426B 18.35
Innate Pharma SA (IPHYF) France $0.423B 0.00
Indivior (INVVY) United States $0.417B 2.48
BioCryst Pharmaceuticals (BCRX) United States $0.407B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.382B 0.00
Siga Technologies (SIGA) United States $0.375B 8.57
Organogenesis Holdings (ORGO) United States $0.370B 0.00
Calithera Biosciences (CALA) United States $0.357B 0.00
Lannett Co Inc (LCI) United States $0.353B 5.69
Harpoon Therapeutics (HARP) United States $0.350B 0.00
DURECT (DRRX) United States $0.342B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.342B 0.00
Recro Pharma (REPH) United States $0.337B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.326B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.314B 0.00
Rafael Holdings (RFL) United States $0.311B 0.00
Concert Pharmaceuticals (CNCE) United States $0.301B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.271B 0.00
OptiNose (OPTN) United States $0.268B 0.00
KalVista Pharmaceuticals (KALV) United States $0.239B 0.00
Ocular Therapeutix (OCUL) United States $0.221B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.217B 0.00
MEI Pharma (MEIP) United States $0.212B 0.00
Taiwan Liposome (TLC) Taiwan $0.185B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.183B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.183B 0.00
Nature's Sunshine Products (NATR) United States $0.178B 30.73
Matinas Biopharma Holdings (MTNB) United States $0.169B 0.00
Jounce Therapeutics (JNCE) United States $0.151B 2.79
IMV INC (IMV) Canada $0.122B 0.00
VAXART, INC (VXRT) United States $0.118B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.114B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.110B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.103B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.098B 0.00
Xeris Pharmaceuticals (XERS) United States $0.097B 0.00
CannTrust Holdings (CTST) Canada $0.095B 0.00
Otonomy (OTIC) United States $0.093B 0.00
Aquestive Therapeutics (AQST) United States $0.089B 0.00
Redhill Biopharma (RDHL) Israel $0.089B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.085B 0.00
Generex Biotechnology (GNBT) United States $0.082B 0.00
Neos Therapeutics (NEOS) United States $0.077B 0.00
Champions Oncology (CSBR) United States $0.075B 0.00
Infinity Pharmaceuticals (INFI) United States $0.069B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.069B 0.00
Onconova Therapeutics (ONTX) United States $0.065B 0.00
MediWound (MDWD) Israel $0.065B 0.00
CV Sciences (CVSI) United States $0.065B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.062B 18.64
RENEURON GP (RNUGF) United Kingdom $0.061B 0.00
Nivalis Therapeutics (ALPN) United States $0.059B 0.00
CTI BioPharma (CTIC) United States $0.058B 0.00
SCYNEXIS (SCYX) United States $0.056B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.052B 0.00
IsoRay (ISR) United States $0.052B 0.00
Natural Alternatives (NAII) United States $0.051B 23.13
AgeX Therapeutics (AGE) United States $0.048B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.048B 0.00
Aclaris Therapeutics (ACRS) United States $0.047B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.045B 0.00
Forward Pharma (FWP) Denmark $0.043B 0.00
Iterum Therapeutics (ITRM) Ireland $0.040B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.040B 0.00
Mannatechorporated (MTEX) United States $0.037B 0.00
PolarityTE (PTE) United States $0.037B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.032B 0.00
Jaguar Animal Health (JAGX) United States $0.030B 0.00
China SXT Pharmaceuticals (SXTC) China $0.028B 0.00
Biomerica (BMRA) United States $0.027B 0.00
PharmAthene (ALT) United States $0.027B 0.00
ElectroCore (ECOR) United States $0.023B 0.00
Vical (BBI) United States $0.022B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.022B 0.00
ProPhase Labs (PRPH) United States $0.021B 0.00
India Globalization Capital (IGC) United States $0.019B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.017B 0.00
Cardiome Pharma (CORV) Canada $0.017B 0.00
Shineco (TYHT) China $0.017B 0.00
Bio-Path Holdings (BPTH) United States $0.016B 0.00
Regulus Therapeutics (RGLS) United States $0.016B 0.00
Cyanotech (CYAN) United States $0.016B 0.00
Hemispherx BioPharma (AIM) United States $0.014B 0.00
Lipocine (LPCN) United States $0.013B 0.00
Heat Biologics (HTBX) United States $0.012B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.012B 0.00
HANCOCK JAFFE (HJLI) United States $0.012B 0.00
Novan (NOVN) United States $0.009B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.009B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.007B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.006B 0.00
Flex Pharma (SLRX) United States $0.004B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
RXi Pharmaceuticals (PHIO) United States $0.002B 0.00
Can-Fite Biopharma (CANF) Israel $0.002B 0.00
Midatech Pharma (MTP) United Kingdom $0.002B 0.00